

# Cumulative Index 1989

## Volume 10

---

<b>March</b>	<b>METABOLIC FUNCTIONS OF THE LUNGS</b> , pages 1-128
<b>June</b>	<b>PULMONARY FUNCTION TESTING</b> , pages 129-296
<b>September</b>	<b>MYCOBACTERIAL DISEASES</b> , pages 297-467
<b>December</b>	<b>PULMONARY MANIFESTATIONS OF SYSTEMIC DISEASE</b> , pages 469-818

---

Note: Page numbers of issues and articles are in **boldface** type.

- A-56268, in treatment of tuberculosis, 358
- Abdominal muscles, role in respiratory muscle function, 201
- Achalasia, pulmonary manifestations of, 621
- Acquired immunodeficiency syndrome (AIDS), effect on immunity, 507
- mycobacterial disease in patients with, 445-463
- nontuberculous mycobacterial infection in, 456-460.
- See also *Mycobacterial infection, nontuberculous, in AIDS*.
- tuberculosis in, 308-309, 447-456. See also *Tuberculosis, in AIDS*.
- Acute lung injury, effect on pulmonary metabolic function, 7-9
- effects of sepsis on, 493
- respiratory tract infections and, in systemic illness, 469-502
- systemic sepsis and, 488-493
- treatment of, with exogenous surfactant, metabolic considerations in, 91-92
- Adrenal cortex disorders, pulmonary manifestations of, 649-650
- $\beta$ -Adrenergic agonists aerosols, for measuring bronchodilator response, 159-160
- $\beta$ -Adrenergic antagonists, pulmonary side effects due to, 577-578
- Adult respiratory distress syndrome (ARDS), clinical syndrome of, 492-493
- sepsis and, 490-491
- Agammaglobulinemia, X-linked, features of, 508-510
- Age, advanced, and respiratory infection in systemic illness, 475-477
- effect on clinical presentation of pneumonia, 475
- effect on DLCO, 191
- in predictions of normal values for PFTs, 136-137
- and tuberculosis, 302-304
- AIDS. See *Acquired immunodeficiency syndrome*.
- Airway, colonization of, mechanisms of, 471-472
- risk factors for, 471
- and systemic illness, 470-472
- obstruction of, in systemic lupus erythematosus, 688-689
- upper, obstruction of, and respiratory function, 523-524
- Airway disease, 711-712
- in rheumatoid arthritis, 700-702
- in Sjögren's syndrome, 711-712
- Alcoholism, respiratory infection in, 478-479
- Allergic angitis, and granulomatosis, 667-668
- Allergy(ies), testing for, bronchoprovocation testing in, 174
- Altitude, in predictions of normal values for PFTs, 139
- Alveolar-capillary surface, fluid transport at, physiology of, 561-562
- Alveolar epithelial cells, type II, role of ion channels in, 30-31
- Alveolar macrophages, role of ion channels in, 31-32
- Alveolar oxygen concentration and altitude, effect on DLCO, 191
- American Thoracic Society (ATS), recommendations of, for spirometry, 148-149
- Amikacin, in treatment of tuberculosis, 359
- drug-resistant, 349
- Aminoglycosides, in treatment of tuberculosis, 359
- Amiodarone pulmonary toxicity, 574-577
- Amyloidosis, pulmonary involvement in, 742
- pulmonary manifestations of, 670-671
- Anastomosis, portopulmonary, in chronic liver disorders, 598
- Anemia, sickle cell, pulmonary involvement in, 730-733
- Antibiotics, for respiratory tract infections in systemic illness, 487-488
- Antigen challenge, for measuring bronchial hyperresponsiveness, 169
- Antimycobacterial agents, 355-364
- $\alpha_1$ -Antitrypsin deficiency, in chronic liver disorders, 603-605
- molecular replacement therapy for, 123-124
- Apnea, CNS abnormalities and, 522-523
- posthyperventilation, in CNS diseases, 528-529
- Apneusis, in CNS diseases, 530

- ARDS. See *Adult respiratory distress syndrome*.
- Arm ergometry, for exercise testing, 278
- Arthritis, rheumatoid, 697-703
- airway disease in, 700-702
- evaluation of, with bronchoalveolar lavage and lung gal-  
lium scanning, 714
- inflammation in, 698-700
- necrobiotic nodules in, 700
- pleural involvement in, 697-698
- pulmonary interstitial fibrosis in, 698-700
- pulmonary vasculitis in, 702
- respiratory disease in, major histocompatibility patterns  
with, 702-703
- respiratory infection in, 480
- unusual pulmonary associations or complications in, 702
- Aspiration, of gastrointestinal contents, 622-629
- Aspirin challenge, for detection of acute bronchospasm in  
asthmatics, 171
- Asthma, confirmation of, bronchoprovocation testing in,  
172-173
- factitious, diagnosis of, bronchoprovocation testing in,  
174
- occupational, challenge testing in, 170-172
- substances associated with, 171
- role of eicosanoids in, 100-101
- Ataxia, in CNS diseases, 530
- Ataxia-telangiectasia, immunodeficiency with, features of,  
515
- Athletes, respiratory function of, effects of training on,  
139
- Atrial septal defects, pulmonary vascular disease in, 557
- ATS. See *American Thoracic Society*.
- Autonomic nervous system, function in respiration, 536-  
537
- Azithromycin (CP-62933), in treatment of tuberculosis,  
359
- Azathioprine, for respiratory tract infections in systemic  
illness, 488
- BACTEC procedure, for detection of *Mycobacterium tu-  
berculosis*, 317-318
- Behavior, compliance, in tuberculosis therapy, action  
steps for improvement of, 376-379
- factors affecting, 375-376
- Behçet's disease, 668
- Bischloroethylnitrosourea (BCNU), metabolism of, 55-56
- Bleomycin, metabolism of, 50-53
- Blood diseases. See *Hematologic disorders*.
- Blood gas instruments, 227-229
- Blood gas tensions and pH, effect on pulmonary metabolic  
function, 6
- Blood gases, arterial, 227-237. See also *Blood sample*.
- Blood sample, analysis of, 231-235
- data calculation in, 231-233
- data transmission in, 233
- proficiency testing programs for, 235-236
- quality control process in, 233-235
- contamination of, minimization of, 230
- procurement of, 229-231
- transport, cooling, and delay of, 230
- Blood volume, in evaluation of endothelial injury in hu-  
man lung, 14-16
- Body plethysmography, for measurement of lung volumes,  
179-180
- Body position, effect on DLCO, 192
- Bone, sarcomas of, metastasis to lung, 774-775
- Bone marrow transplantation, in hematologic malignancy-  
associated disorders, pulmonary involvement in, 742
- respiratory infection in, 483-484
- Breast, carcinoma of, metastasis to lung, 771-773
- Bronchial hyperresponsiveness, measurement of, methods  
of, 167-170
- nonspecific, diseases associated with, 172
- pathogenesis of, 165-167
- Bronchial inhalation challenge techniques, 167-172
- Bronchiolitis, and rheumatoid arthritis, 700-701
- Bronchoalveolar lavage, for evaluation of collagen vascular  
diseases, 712-714
- Bronchodilators, response to, 155-164
- clinical implications of, 160-162
- criteria for, 161
- measurement of, agents for, 159-160
- partial flow-volume curves for, 157-158
- physiologic tests for, 155-157
- plethysmography for, 158
- variability of, 159
- Bronchoprovocation testing, 165-176
- for allergy testing, 174
- clinical uses of, 172-174
- for confirmation of asthma diagnosis, 172-173
- for diagnosis of factitious asthma, 174
- in diagnosis of reactive airways dysfunction syndrome,  
173-174
- for evaluation of pulmonary symptoms, 173
- techniques of, 167-172
- Calcium, influx of, in endothelial cells, 33
- Cancer. See also specific types.
- respiratory infection in, 482
- Caplan's syndrome, 700
- Capreomycin, in treatment of tuberculosis, 328
- drug-resistant, 349
- Carbon dioxide, content of, calculation of, 261
- end-tidal, 251
- noninvasive monitoring of, 250-251
- response to, in assessment of ventilatory control, 220-  
222
- Carbon dioxide pressure, arterial, estimation of, 260-261
- mixed venous, measurement of, 256-260
- Carbon dioxide rebreathing methods, for measurement of  
cardiac output, 255-264
- Carbon monoxide diffusing capacity (DLCO), 187-197
- alteration of, factors causing, 195
- clinical applications of, 194-196
- in evaluation of impairment from respiratory disorders,  
196
- measurement of, 188-190
- interpretation of data in, 190-192
- laboratory issues in, 190
- single-breath techniques for, 189
- morphometric, 190
- prediction of normal values of, 192-194
- rebreathing, 189-190
- steady-state, 189
- Carboxyhemoglobin, effect on DLCO, 191-192
- Cardiac disease, and alteration in pulmonary function test-  
ing, 567-571
- alterations in pulmonary vasculature due to, 545-550
- pleural manifestations of, 571-574
- pulmonary and pleural complications of, 545-592
- Cardiac output, measurement of, by carbon dioxide re-  
breathing methods, 255-264
- in non-steady-state conditions, 261-263
- Cardiopulmonary exercise testing, 277-291
- Cartilage hair hypoplasia, features of, 506-507
- Celiac disease, pulmonary manifestations of, 630

- Central inspiratory neuromuscular drive, assessment of, 216-217
- Central nervous system, function in respiration, 521-531
- Central nervous system diseases, abnormal breathing patterns in, 528-530
- Central respiratory neural drive, assessment of, 216 measurements of, 218-219
- Central respiratory neuromuscular drive, measurements of, 219-220
- Cerebellar atrophy, and respiratory function, 530
- Cerebral cortex, damage to, and respiratory function, 526-528
- Cervix, carcinoma of, metastasis to lung, 771
- CGP 7040, in treatment of tuberculosis, 357-358
- Charcot-Marie-Tooth disease, effect on respiratory system, 534-536
- Chemical drive, measurements of, 220-224
- Chemotherapy, for tuberculosis, background of, 342-343. See also *Tuberculosis, treatment of.*
- Cheyne-Stokes respiration, in CNS diseases, 529
- Chloride channels, in tracheal epithelial cells, 27-29
- Cholangitis, primary sclerosing, in chronic liver disorders, 605
- Churg-Strauss disease, 667-668
- Cigarette smoke, effect on mucociliary clearance of particulate matter, 30
- Ciprofloxacin, in treatment of drug-resistant tuberculosis, 350
- Cirrhosis, primary biliary, pulmonary manifestations of, 601-603
- pulmonary manifestations of, 594-598
- Clara cells, ion transport in, 30
- Clofazimine, in treatment of tuberculosis, 358
- Closed-circuit helium dilution, for measurement of lung volumes, 177-179
- CNS. See *Central nervous system.*
- Coagulation disorders, and the lungs, 724-730
- Cold air isocapnic hyperventilation challenge test, for measuring bronchial hyperresponsiveness, 169
- Colitis, ulcerative, pulmonary manifestations of, 629
- Collagen vascular diseases, evaluation of, with bronchoalveolar lavage and lung gallium scanning, 712-714
- pulmonary manifestations of, 677-722
- respiratory infection in, 479-480
- Colon, carcinoma of, metastasis to lung, 768-769
- Congenital heart disease, and abnormalities in pulmonary function, 570-571
- as cause of pulmonary vascular disease, 550-560
- Congestive heart failure, chronic, abnormalities in pulmonary function testing in, 567-570
- transudative effusions caused by, 572-573
- Connective tissue disease, mixed, pulmonary involvement in, 708-709
- Correctional institutions (prisons), tuberculosis in, 402-404
- Corticosteroids, for respiratory tract infections in systemic illness, 488
- for systemic lupus erythematosus pleuritis, 679-681
- CQQ (gangaminin), in treatment of tuberculosis, 360
- Crohn's disease, pulmonary manifestations of, 629
- Cutaneous infections, mycobacterial, 419-429
- Cycle ergometer, for exercise testing, 278
- protocols for, 279-280
- Cyclophosphamide, metabolism of, 54-55
- for respiratory tract infections in systemic illness, 488
- for Wegener's granulomatosis, 666-667
- Cycloserine, in treatment of tuberculosis, 328
- drug-resistant, 350
- Cyclosporine, for respiratory tract infections in systemic illness, 488
- Cystic fibrosis, treatment of, molecular biology in, 112-123
- Diabetes mellitus, pulmonary manifestations of, 650-651
- and respiratory function, 537
- respiratory infection in, 477-478
- and tuberculosis, 309
- Diaphragm, role in respiratory muscle function, 199-200, 208-211
- DiGeorge syndrome, features of, 505-506
- Dihydropyranocyanine A, in treatment of tuberculosis, 360
- Disseminated intravascular coagulation, treatment of, 728-729
- Diurnal variation, effect on DLCO, 192
- DLCO. See *Carbon monoxide diffusing capacity (DLCO).*
- DNA cloning, 120-121
- DNA disassociation, 120
- DNA expression libraries, role in diagnosis and treatment of pulmonary disease, 121-122
- DNA structure, 119
- Dressler's syndrome, clinical manifestations and treatment of, 573-574
- Drug-susceptibility tests, for identification of *Mycobacterium* species, 319-320
- Dwarfism, short-limbed, immunodeficiency with, features of, 506-507
- Dyscrasias, plasma cell, pulmonary involvement in, 741-742
- Eicosanoids, in control of normal lung function, 96-101
- in lung injury, 101-102
- lung metabolism of, 95-105
- measurement of, 97-98
- role in asthma and increased airway reactivity, 100-101
- role in control of lung circulation, 99-100
- treatment of lung disease by, 102-103
- Eisenmenger's syndrome, pulmonary vascular disease in, 557-558
- Elderly, tuberculosis in, 397-401
- Ellipsoid technique, for measurement of lung volumes, 180
- Emphysema, effect on pulmonary metabolic function, 5-6
- Endocarditis, right-sided, 579-584
- bacteriology of, 579-580
- clinical manifestations of, 580-581
- etiology of, 579
- prognosis of, 585
- treatment of, 581-585
- Endocrine diseases, pulmonary manifestations of, 645-653
- Endometrium, carcinoma of, metastasis to lung, 771
- Endoscopic sclerotherapy, pulmonary, complications of, in patients with liver disease, 606
- Endothelial cells, role of ion channels in, 32-33
- Endothelial injury, in human lung, evaluation of, 13-24
- endothelial metabolic functions in, 18-22
- endothelial permeability in, 16-18
- vascular and extravascular volumes, 14-16
- Endothelial metabolic functions, in evaluation of endothelial injury in human lung, 18-22
- Endothelial permeability, in evaluation of endothelial injury in human lung, 16-18
- Endotracheal tubes, for respiratory tract infections in systemic illness, 488
- Environment, in prevention of tuberculosis, 367-368

- ARDS. See *Adult respiratory distress syndrome*.
- Arm ergometry, for exercise testing, 278
- Arthritis, rheumatoid, 697-703
- airway disease in, 700-702
- evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714
- inflammation in, 698-700
- necrobiotic nodules in, 700
- pleural involvement in, 697-698
- pulmonary interstitial fibrosis in, 698-700
- pulmonary vasculitis in, 702
- respiratory disease in, major histocompatibility patterns with, 702-703
- respiratory infection in, 480
- unusual pulmonary associations or complications in, 702
- Aspiration, of gastrointestinal contents, 622-629
- Aspirin challenge, for detection of acute bronchospasm in asthmatics, 171
- Asthma, confirmation of, bronchoprovocation testing in, 172-173
- factitious, diagnosis of, bronchoprovocation testing in, 174
- occupational, challenge testing in, 170-172
- substances associated with, 171
- role of eicosanoids in, 100-101
- Ataxia, in CNS diseases, 530
- Ataxia-telangiectasia, immunodeficiency with, features of, 515
- Athletes, respiratory function of, effects of training on, 139
- Atrial septal defects, pulmonary vascular disease in, 557
- ATS. See *American Thoracic Society*.
- Autonomic nervous system, function in respiration, 536-537
- Azithromycin (CF-62933), in treatment of tuberculosis, 359
- Azathioprine, for respiratory tract infections in systemic illness, 488
- BAC1EC procedure, for detection of *Mycobacterium tuberculosis*, 317-318
- Behavior, compliance, in tuberculosis therapy, action steps for improvement of, 376-379
- factors affecting, 375-376
- Behcet's disease, 668
- Bischloroethylnitrosourea (BCNU), metabolism of, 55-56
- Bleomycin, metabolism of, 50-53
- Blood diseases. See *Hematologic disorders*.
- Blood gas instruments, 227-229
- Blood gas tensions and pH, effect on pulmonary metabolic function, 6
- Blood gases, arterial, 227-237. See also *Blood sample*.
- Blood sample, analysis of, 231-235
- data calculation in, 231-233
- data transmission in, 233
- proficiency testing programs for, 235-236
- quality control process in, 233-235
- contamination of, minimization of, 230
- procurement of, 229-231
- transport, cooling, and delay of, 230
- Blood volume, in evaluation of endothelial injury in human lung, 14-16
- Eddy plethysmography, for measurement of lung volumes, 179-180
- Body position, effect on DLCO, 192
- Bone, sarcomas of, metastasis to lung, 774-775
- Bone marrow transplantation, in hematologic malignancy-associated disorders, pulmonary involvement in, 742
- respiratory infection in, 483-484
- Breast, carcinoma of, metastasis to lung, 771-773
- Bronchial hyperresponsiveness, measurement of, methods of, 167-170
- nonspecific, diseases associated with, 172
- pathogenesis of, 165-167
- Bronchial inhalation challenge techniques, 167-172
- Bronchiolitis, and rheumatoid arthritis, 700-701
- Bronchoalveolar lavage, for evaluation of collagen vascular diseases, 712-714
- Bronchodilators, response to, 155-164
- clinical implications of, 160-162
- criteria for, 161
- measurement of, agents for, 159-160
- partial flow-volume curves for, 157-158
- physiologic tests for, 155-157
- plethysmography for, 158
- variability of, 159
- Bronchoprovocation testing, 165-176
- for allergy testing, 174
- clinical uses of, 172-174
- for confirmation of asthma diagnosis, 172-173
- for diagnosis of factitious asthma, 174
- in diagnosis of reactive airways dysfunction syndrome, 173-174
- for evaluation of pulmonary symptoms, 173
- techniques of, 167-172
- Calcium, influx of, in endothelial cells, 33
- Cancer. See also specific types.
- respiratory infection in, 482
- Caplan's syndrome, 700
- Capreomycin, in treatment of tuberculosis, 328
- drug-resistant, 349
- Carbon dioxide, content of, calculation of, 261
- end-tidal, 251
- noninvasive monitoring of, 250-251
- response to, in assessment of ventilatory control, 220-222
- Carbon dioxide pressure, arterial, estimation of, 260-261
- mixed venous, measurement of, 256-260
- Carbon dioxide rebreathing methods, for measurement of cardiac output, 255-264
- Carbon monoxide diffusing capacity (DLCO), 187-197
- alteration of, factors causing, 195
- clinical applications of, 194-196
- in evaluation of impairment from respiratory disorders, 196
- measurement of, 188-190
- interpretation of data in, 190-192
- laboratory issues in, 190
- single-breath techniques for, 189
- morphometric, 190
- prediction of normal values of, 192-194
- rebreathing, 189-190
- steady-state, 189
- Carboxyhemoglobin, effect on DLCO, 191-192
- Cardiac disease, and alteration in pulmonary function testing, 567-571
- alterations in pulmonary vasculature due to, 545-550
- pleural manifestations of, 571-574
- pulmonary and pleural complications of, 545-592
- Cardiac output, measurement of, by carbon dioxide rebreathing methods, 255-264
- in non-steady-state conditions, 261-263
- Cardiopulmonary exercise testing, 277-291
- Cartilage hair hypoplasia, features of, 506-507
- Celiac disease, pulmonary manifestations of, 630

- Central inspiratory neuromuscular drive, assessment of, 216-217
- Central nervous system, function in respiration, 521-531
- Central nervous system diseases, abnormal breathing patterns in, 528-530
- Central respiratory neural drive, assessment of, 216
- Measurements of, 218-219
- Central respiratory neuromuscular drive, measurements of, 219-220
- Cerebellar atrophy, and respiratory function, 530
- Cerebral cortex, damage to, and respiratory function, 526-528
- Cervix, carcinoma of, metastasis to lung, 771
- CGP 7040, in treatment of tuberculosis, 357-358
- Charcot-Marie-Tooth disease, effect on respiratory system, 534-536
- Chemical drive, measurements of, 220-224
- Chemotherapy, for tuberculosis, background of, 342-343.
- See also *Tuberculosis, treatment of.*
- Cheyne-Stokes respiration, in CNS diseases, 529
- Chloride channels, in tracheal epithelial cells, 27-29
- Cholangitis, primary sclerosing, in chronic liver disorders, 605
- Churg-Strauss disease, 667-668
- Cigarette smoke, effect on mucociliary clearance of particulate matter, 30
- Ciprofloxacin, in treatment of drug-resistant tuberculosis, 350
- Cirrhosis, primary biliary, pulmonary manifestations of, 601-603
- pulmonary manifestations of, 594-598
- Clara cells, ion transport in, 30
- Clofazimine, in treatment of tuberculosis, 358
- Closed-circuit helium dilution, for measurement of lung volumes, 177-179
- CNS. See *Central nervous system.*
- Coagulation disorders, and the lungs, 724-730
- Cold air isocapnic hyperventilation challenge test, for measuring bronchial hyperresponsiveness, 169
- Colitis, ulcerative, pulmonary manifestations of, 629
- Collagen vascular diseases, evaluation of, with bronchoalveolar lavage and lung gallium scanning, 712-714
- pulmonary manifestations of, 677-722
- respiratory infection in, 479-480
- Colon, carcinoma of, metastasis to lung, 768-769
- Congenital heart disease, and abnormalities in pulmonary function, 570-571
- as cause of pulmonary vascular disease, 550-560
- Congestive heart failure, chronic, abnormalities in pulmonary function testing in, 567-570
- transudative effusions caused by, 572-573
- Connective tissue disease, mixed, pulmonary involvement in, 708-709
- Correctional institutions (prisons), tuberculosis in, 402-404
- Corticosteroids, for respiratory tract infections in systemic illness, 488
- for systemic lupus erythematosus pleuritis, 679-681
- CQQ (gangaminin), in treatment of tuberculosis, 360
- Crohn's disease, pulmonary manifestations of, 629
- Cutaneous infections, mycobacterial, 419-429
- Cycle ergometer, for exercise testing, 278
- protocols for, 279-280
- Cyclophosphamide, metabolism of, 54-55
- for respiratory tract infections in systemic illness, 488
- for Wegener's granulomatosis, 666-667
- Cycloserine, in treatment of tuberculosis, 328
- drug-resistant, 350
- Cyclosporine, for respiratory tract infections in systemic illness, 488
- Cystic fibrosis, treatment of, molecular biology in, 122-123
- Diabetes mellitus, pulmonary manifestations of, 650-651
- and respiratory function, 537
- respiratory infection in, 477-478
- and tuberculosis, 309
- Diaphragm, role in respiratory muscle function, 199-200, 208-211
- DiGeorge syndrome, features of, 505-506
- Dihydromycoplanacin A, in treatment of tuberculosis, 360
- Disseminated intravascular coagulation, treatment of, 728-729
- Diurnal variation, effect on DLCO, 192
- DLCO. See *Carbon monoxide diffusing capacity (DLCO).*
- DNA cloning, 120-121
- DNA disassociation, 120
- DNA expression libraries, role in diagnosis and treatment of pulmonary disease, 121-122
- DNA structure, 119
- Dressler's syndrome, clinical manifestations and treatment of, 573-574
- Drug-susceptibility tests, for identification of *Mycobacterium* species, 319-320
- Dwarfism, short-limbed, immunodeficiency with, features of, 506-507
- Dyscrasias, plasma cell, pulmonary involvement in, 741-742
- Eicosanoids, in control of normal lung function, 96-101
- in lung injury, 101-102
- lung metabolism of, 95-105
- measurement of, 97-98
- role in asthma and increased airway reactivity, 100-101
- role in control of lung circulation, 99-100
- treatment of lung disease by, 102-103
- Eisenmenger's syndrome, pulmonary vascular disease in, 557-558
- Elderly, tuberculosis in, 397-401
- Ellipsoid technique, for measurement of lung volumes, 180
- Emphysema, effect on pulmonary metabolic function, 5-6
- Endocarditis, right-sided, 579-584
- bacteriology of, 579-580
- clinical manifestations of, 580-581
- etiology of, 579
- prognosis of, 585
- treatment of, 581-585
- Endocrine diseases, pulmonary manifestations of, 645-653
- Endometrium, carcinoma of, metastasis to lung, 771
- Endoscopic sclerotherapy, pulmonary, complications of, in patients with liver disease, 606
- Endothelial cells, role of ion channels in, 32-33
- Endothelial injury, in human lung, evaluation of, 13-24
- endothelial metabolic functions in, 18-22
- endothelial permeability in, 16-18
- vascular and extravascular volumes, 14-16
- Endothelial metabolic functions, in evaluation of endothelial injury in human lung, 18-22
- Endothelial permeability, in evaluation of endothelial injury in human lung, 16-18
- Endotracheal tubes, for respiratory tract infections in systemic illness, 488
- Environment, in prevention of tuberculosis, 367-368



- Environmental exposures, in predictions of normal values for PFTs, 138-139
- Erythrocyte disorders, pulmonary involvement in, 730-735
- Esophageal atresia, pulmonary manifestations of, 617-619
- Esophageal disease, pulmonary manifestations of, 619-622
- Ethambutol, in treatment of tuberculosis, 326-327
- Ethionamide, in treatment of tuberculosis, 327-328  
drug-resistant, 349-350
- Ethnic groups, tuberculosis among, 304-305
- Exercise, arterial desaturation during, prediction of, 195-196  
effect on DLCO, 192
- Exercise challenge, for measuring bronchial hyperresponsiveness, 169-170
- Exercise testing, cardiopulmonary, assessment of symptoms during, 285  
equipment for, 289  
stage 1, 280-285  
stage 4, 288-289  
stages 2 and 3, 285-288
- Exercise tests, protocols for, 279-280  
types of, 277-279
- Felty's syndrome, respiratory infection in, 490
- Fick principle, 255
- First-order kinetics, effect on pulmonary metabolic function, 3-4
- Flow-volume curves, definition of, 146  
partial, for measuring bronchodilator response, 157-158  
spirometry and, 145-154
- Folate antagonists, in treatment of tuberculosis, 359-360
- Free radical injury, cellular protection from, 41-42
- Free radical production, mechanisms of, 38-39  
by paraquat, 45
- Free radicals, effects on lung metabolism, 37-47  
sources of, 39-41
- Fulminant hepatic failure, pulmonary manifestations of, 593-594
- Fusidic acid, in treatment of tuberculosis, 360-361
- Gallium scanning, lung, for evaluation of collagen vascular diseases, 712-714
- Gangamycin (CQQ), in treatment of tuberculosis, 360
- Gas dilution techniques, for measurement of lung volumes, 177-179  
closed-circuit helium dilution technique, 177-179  
open-circuit nitrogen washout technique, 179
- Gastrointestinal disease, aspiration and, 622-629  
pulmonary manifestations of, 617-643
- Germ cell tumors, metastasis to lung, 765-767
- Goodpasture's syndrome, 655-661  
clinical manifestations of, 657-658  
pathogenesis of, 656-657  
pathology and diagnosis of, 658-660  
radiographic manifestations of, 658  
therapy and prognosis of, 660-661
- Granulomatosis, lymphomatoid. *See Lymphomatoid granulomatosis.*
- Wegener's. *See Wegener's granulomatosis.*
- Guillain-Barré syndrome, effect on respiratory system, 534-535
- Head and neck cancer, metastasis to lung, 773-774
- Heart, septic pulmonary emboli arising from, 579-584
- Heart disease, respiratory infection in, 482
- Heart-lung transplantation, respiratory infection in, 485-486
- Heart transplantation, respiratory infection in, 485
- Height, in predictions of normal values for PFTs, 136
- Hematologic disorders, effect on lungs, 723-746  
malignancy-associated, in bone marrow transplantation, pulmonary involvement in, 742  
immunosuppression in, 738-739  
infection in, 738-739  
mediastinal compression/mass effect on, 736-737  
pulmonary infiltration in, 737-738  
pulmonary involvement in, 736-742
- Hemeprotein peroxidases, role in oxidative insult to lung, 79
- Hemoglobin concentration, effect on DLCO, 191
- Hemoglobinopathies, associated with abnormal oxygen affinities, pulmonary involvement in, 734
- Hemophilia, treatment of, 728
- Hemoptysis, pulmonary, 724-729. *See also Pulmonary hemorrhage.*
- Hemorrhage, pulmonary. *See Pulmonary hemorrhage.*
- Hepatitis, chronic active, pulmonary manifestations of, 605
- Hepatocellular carcinoma, metastasis to lung, 770
- Hereditary disorders, pulmonary manifestations of, 636-638
- Histamine challenge, for measuring bronchial hyperresponsiveness, 168-169
- HIV infection. *See Human immunodeficiency virus infection.*
- Homeless shelters, tuberculosis in, 404
- 5-HT. *See 5-Hydroxytryptamine.*
- Human immunodeficiency virus (HIV) infection, effect on immunity, 507-508  
effect on tuberculosis patients in prisons, 404  
mycobacterial disease in patients with, 445-463  
role in expression of tuberculosis, 307-308, 446-447
- Hydralazine, as cause of lupuslike syndrome, 694-695
- 5-Hydroxytryptamine (5-HT), lung metabolism of, 59-70.  
*See also Serotonin.*
- Hyperimmunoglobulin E syndrome (Job's syndrome), features of, 516
- Hyperleukocytosis, pulmonary involvement in, 736-737
- Hypertension, left atrial, effect on pulmonary metabolic function, 5  
pulmonary, in chronic liver disorders, 600-601  
histologic changes in, 551-555  
pulmonary venous, as cause of pulmonary vascular disease, 560-567
- Hyperthyroidism, pulmonary manifestations of, 647-648
- Hyperventilation, central neurogenic, in CNS diseases, 529-530
- Hypothyroidism, pulmonary manifestations of, 645-647
- Hypoventilation, central alveolar, CNS abnormalities and, 523
- Hypoxia, response to, in assessment of ventilatory control, 222-224
- Immune cells, in tuberculosis, 445-446
- Immune response, components of, 503-505
- Immunity, cell-mediated, defects in, 505-508  
acquired primary disorders, 507-508  
congenital disorders, 505-507  
humoral, defects in, 508-512  
acquired, 512  
congenital, 508-512

- Immunodeficiency, with ataxia-telangiectasia, features of, 515  
 with elevated IgM levels, features of, 510
- Immunodeficiency disorders, severe combined, features of, 515-516
- Immunodeficiency states, congenital and acquired, pulmonary consequences of, 503-519
- Immunomodulators, in treatment of tuberculosis, 361
- Immunosuppression, in hematologic malignancy-associated disorders, 739
- Infection. See also specific types of infections.  
 in hematologic malignancy-associated disorders, 739  
 pulmonary. See *Pulmonary infection*.
- Infection control, in pulmonary function testing, 130-132
- Infectious diseases, pulmonary manifestations of, 671
- Inflammation, in rheumatoid arthritis, 698-700
- Inflammatory bowel disease, sulfasalazine for, pulmonary complications of, 629-630
- Intercostal muscles, role in respiratory muscle function, 200
- Interstitial lung disease, DLCO in, 194  
 in Sjögren's syndrome, 712
- Intestinal disease, pulmonary manifestations of, 629-630
- Ion channels, in alveolar macrophages, 31-32  
 in Clara cells, 30  
 in endothelial cells, 32-33  
 in metabolic regulation of respiratory cells, 25-36  
 in tracheal epithelial cells, 26-30  
 in type II alveolar epithelial cells, 30-31
- Ipratropium bromide, for measuring bronchodilator response, 160
- Ischemia and reperfusion injury, role of xanthine oxidase in, 75-79
- Isoniazid, in prevention of tuberculosis, 369-371, 372-373  
 in treatment of tuberculosis, 324-325
- Jails, tuberculosis in, 404
- Job's syndrome, features of, 516
- Kanamycin, in treatment of tuberculosis, 328  
 drug-resistant, 349
- $\beta$ -Lactams, in treatment of tuberculosis, 359
- Liposome encapsulation, of new antimycobacterial agents, 361-362
- Liver diseases, chronic, 594-605  
 respiratory infection in, 478-479  
 effect on interpretation of pulmonary function tests, 605-607  
 pulmonary aspects of, 593-607
- Liver function, effect of liver transplantation on, 609-611
- Liver transplantation, effect on liver function, 609-611  
 pulmonary aspects of, 607-611  
 postoperative complications, 608-609  
 pretransplant pulmonary evaluation, 607-608  
 respiratory infection in, 485
- Long-term care facilities, tuberculosis in, 401-402
- Lung, anatomy and physiology of, 723-724  
 coagulation disorders and, 724-730  
 endothelial injury in, evaluation of, 13-24. See also *Endothelial injury, in human lung, evaluation of*.  
 hematologic disorders affecting, 723-746. See also *Pulmonary hemorrhage* and specific disorders.  
 hematologic malignancies affecting, 736-742. See also *Hematologic disorders*.  
 host defense of, components of, 504  
 5-HT uptake and metabolism in, 61-62  
 metabolic functions of, interpretation of, 1-12  
 issue on, 1-125. See also *Pulmonary metabolic functions*.  
 nonpulmonary malignancies in, metastatic spread of, 747-807. See also *Lung disease, metastatic*.  
 oxidative insult to, role of heme protein peroxidases in, 79  
 role of mitochondrial electron transport in, 71-72  
 role of phagocyte NADPH oxidase in, 73-75
- Lung antioxidant enzymatic defenses, 41
- Lung cancer, primary, metastatic lung cancer vs, 753-754  
 and scleroderma, 705  
 treatment of, molecular biology in, 122
- Lung circulation, role of eicosanoids in control of, 99-100
- Lung disease, combined, lung volume measurements in, 184  
 5-HT uptake in, applications and limitations of measuring, 67-68  
 interstitial, DLCO in, 194  
 metastatic, pulmonary and pleural manifestations of, 747-807  
 mycobacterial, 423-428  
*Mycobacterium avium* and *Mycobacterium kansasii* as cause of, 432-433  
 obstructive, DLCO in, 194  
 lung volume measurements in, 182-183  
 pathophysiology of, role of 5-HT in, 65-67  
 restrictive, lung volume measurements in, 183-184  
 treatment of, by manipulation of eicosanoid system, 102-103
- Lung inflation, effect on pulmonary metabolic function, 6
- Lung injury, effects on 5-HT uptake, 63-65  
 oxygen, in humans, 43-44  
 role of eicosanoids in, 101-102
- Lung metabolism, of eicosanoids, 95-105  
 free radical effects on, 37-47  
 paraquat poisoning and, 45  
 of serotonin, 59-70  
 of xenobiotic compounds, 49-58
- Lung volume, effect on DLCO, 191  
 measurement of, 177-186  
 body plethysmography for, 179-180  
 clinical application of, 182-184  
 closed-circuit helium dilution technique for, 177-179  
 comparison of different techniques, 180-181  
 open-circuit nitrogen washout technique for, 179  
 radiographic techniques for, 180  
 normal predictive values for, 181-182
- Lupus syndrome, drug-induced, 578-579
- Lymphadenitis, superficial mycobacterial, in children and adolescents, 386, 413-414
- Lymphomatoid granulomatosis, 668-669
- Macrolides, in treatment of tuberculosis, 358-359
- Malnutrition, respiratory infection in, 486-487
- Medulla oblongata, destruction of, and respiratory function, 522-527
- Melanomas, malignant, metastasis to lung, 765
- Meningitis, in children and adolescents, 387
- Mental hospitals, tuberculosis in, 401-402
- Metabisulfite challenge, for detection of acute bronchospasm in asthmatics, 171
- Metabolic diseases, pulmonary manifestations of, 645-653
- Metabolic regulation of respiratory cells, ion channels in, 25-36

- Metastasis. See *Neoplasm metastasis*.
- Methacholine inhalation challenge, for measuring bronchial hyperresponsiveness, 168
- Methotrexate, metabolism of, 56
- Microembolism, effect on pulmonary metabolic function, 5-6
- Mineral metabolism, abnormalities of, pulmonary manifestations of, 651
- Mitochondrial electron transport, role in oxidative insult to lung, 71-72
- Mitral stenosis, hemoptysis due to, 566-567  
natural history of, 563-564  
pulmonary vascular disease due to, 562-567  
etiology of, 565-566  
following surgical correction, 565  
histologic changes, 564-565
- Mixed-order conditions, effect on pulmonary metabolic function, 3-4
- Molecular replacement therapy, for  $\alpha_1$ -antitrypsin deficiency, 123-124
- Mouth occlusion pressure, measurements of, 220
- Multiple sleep latency test, for evaluation of respiratory disorders during sleep, 266, 269-271
- Myasthenia gravis, effect on respiratory system, 535
- Mycobacterial disease, diagnosis of, 433-435  
in HIV-infected patients, 445-463  
issue on, 297-463  
nontuberculous, epidemiology of, 407-417  
of lymph node, 414  
prevalence of disease, 411-412  
prevalence of infection, 410-411  
pulmonary, 412-414  
of skin and soft tissues, 414-415  
transmission of, 408-410  
nontuberculous mycobacteria as cause of, disseminated, 415
- Mycobacterial infection, molecular immunology of, 121  
nontuberculous, in AIDS, 456-460  
clinical features of, 458-459  
diagnosis of, 459  
treatment of, 459-460
- Mycobacteriology laboratory, in diagnosis of tuberculosis, 315-322  
BACTEC procedure, 317-318  
drug-susceptibility tests, 319-320  
genetic and immunologic probes, 318-319  
mycolic acid patterns, 319  
routine procedures, 316-317
- Mycobacterium avium* complex, as cause of disease, 431-432  
clinical characteristics of, 432-433  
management and treatment of, 436-439
- Mycobacterium avium* complex infection, immune cells in, and role of HIV, 458
- Mycobacterium chelonae*, as cause of cutaneous and pulmonary infections, 419-429  
cutaneous disease caused by, 420-422  
disseminated disease caused by, 422-423  
microbiology of, 419-420  
pulmonary disease caused by, 423-428
- Mycobacterium fortuitum*, as cause of cutaneous and pulmonary infections, 419-429  
cutaneous disease caused by, 420-422  
disseminated disease caused by, 422-423  
microbiology of, 419-420  
pulmonary disease caused by, 423-428
- Mycobacterium fortuitum* complex, management and treatment of, 440
- Mycobacterium kansasii*, clinical characteristics of, 432-433
- Mycobacterium kansasii* disease, management and treatment of, 439-440
- Mycobacterium mageritense*, as cause of disease, 440
- Mycobacterium marinum*, management and treatment of, 440
- Mycobacterium simiae*, as cause of disease, 440
- Mycobacterium tuberculosis*, diagnosis of, 433-435  
management and treatment of, 435-436  
mycobacteriophage types of, 320
- Mycobacterium tuberculosis* complex, 315-316  
treatment of, new antimycobacterial agents for, 355-364
- Mycobacterium ulcerans*, as cause of disease, 440
- Mycobacterium xenopi*, as cause of disease, 440
- Mycolic acids, pattern of, for identification of *Mycobacterium* species, 319
- Myeloma, multiple, pulmonary involvement in, 741-742
- Myeloproliferative disorders, chronic, pulmonary involvement in, 734-736
- Myotonia congenita, effect on respiratory system, 536
- Myotonic muscular dystrophy, effect on respiratory system, 536
- NADPH cytochrome P<sub>450</sub> reductase, role in microsomal mixed function oxidase system, 72-73
- Narcolepsy, 273-274
- Nasogastric tubes, for respiratory tract infections in systemic illness, 488
- Neoplasm metastasis, pleural, 776-794  
clinical manifestations of, 783-788  
diagnosis of, 788-790  
etiology and incidence of, 776-777  
pathogenesis of, 777-783  
prognosis of, 790  
treatment of, 790-794  
process of, biology of, 747-752  
pulmonary, 774-775  
detection of, by imaging, 754-755  
growth rates of, determined by imaging techniques, 755-756  
malignant melanomas and, 765  
primary lung cancer vs, 753-754  
radiographic patterns of, 756-775  
tissue diagnosis of, techniques for obtaining, 764-765  
treatment of, 775-776
- Neurologic disorders, and respiration, 521-543  
management of, 537-538
- Nezelof's syndrome, features of, 506
- Nitrofurantoin, metabolism of, 53-54
- Nonsteroidal anti-inflammatory drugs (NSAIDs), for respiratory tract infections in systemic illness, 487
- Nucleic acid, cloning of, in diagnosis and treatment of tuberculosis, 119-121
- Nursing homes, tuberculosis in, 399-401
- Obstructive lung disease, DLCO in, 194  
lung volume measurements in, 182-183
- Open-circuit nitrogen washout, for measurement of lung volumes, 179
- Osmotic challenge, for measuring bronchial hyperresponsiveness, 170
- Ovaries, carcinoma of, metastasis to lung, 770-771
- Oxidant/antioxidant metabolism, 49-50
- Oxidant injury, molecular sites of, 42-43



- Oximetry, definition of, 242-243  
 non-pulse transmission, 244-245  
 noninvasive, 242-250  
 pulse, 245-250  
   clinical experience with, 248-250  
   dyshemoglobins in, 246-248  
   historical development of, 245-246
- Oxygen, noninvasive monitoring of, 239-250  
   clinical experience with, 240-241  
   historical developments of, 239-240  
   practical considerations in, 240
- Oxygen lung injury, in humans, 43-44
- Oxygen uptake, maximal, measurement of, during exercise, 280
- PAF. See *Platelet activating factor*.
- Pancreas, carcinoma of, metastasis to lung, 770
- Pancreatitis, pulmonary manifestations of, 630-636
- Para-aminosalicylic acid, in treatment of tuberculosis, 327  
   drug-resistant, 350
- Paraquat, free radical production by, 45
- Paraquat poisoning, and lung metabolism, 45  
   treatment of, 45-46
- Parathyroid disorders, pulmonary manifestations of, 648-649
- Parkinsonism, and respiratory function, 530
- Patent ductus arteriosus, pulmonary vascular disease in, 557
- D-Penicillamine, for scleroderma pulmonary disease, 705-706
- Perfused vascular surface area, effect on pulmonary metabolic function, 4-7
- Peripheral nervous system, function in respiration, 531-536
- Peripheral neuromuscular control, neuropathologic conditions and, 533-536
- PFT. See *Pulmonary function testing*.
- Phagocyte NADPH oxidase, role in oxidative insult to lung, 73-75
- Phenazines, in treatment of tuberculosis, 358
- Pituitary disorders, pulmonary manifestations of, 649
- Planimetry method, for measurement of lung volumes, 180
- Plasma exchange therapy, for Goodpasture's syndrome, 660-661
- Platelet activating factor, 109-110  
   biologic activities of, 108-109  
   biosynthesis of, 107-108  
   effects on pulmonary function, 110-113  
   in pulmonary pathobiology, 107-118  
   pulmonary vascular alterations caused by, 113-115  
   role in pulmonary disease, 115  
   structure of, 107
- Plethysmography, for measuring bronchodilator response, 158  
   respiratory-inductive, 251
- Pleura, involvement of, in rheumatoid arthritis, 697-698  
   in systemic lupus erythematosus, 678-681
- Pleural effusions, in chronic liver disorders, 600  
   malignant, 777-783  
     diagnosis of, 788-790  
     prognosis of, 790  
   paramalignant, 777-783  
   systemic lupus erythematosus, diagnosis of, 679
- Pleural space, physiology of, 571-572
- Pleural "spiders", in chronic liver disorders, 599
- Pleuritis, systemic lupus erythematosus, treatment of, 679-681
- Pleuropulmonary disease, cardiovascular drugs and, 574-579
- Pneumoconiosis, rheumatoid, 700
- Pneumonia, aspiration, predisposing factors for, 624  
   clinical presentation of, effects of systemic illness and age on, 475  
   *Pneumocystis carinii*, in HIV-infected patients, 507  
   in systemic illness, clinical conditions causing, 475-488.  
   See also *Respiratory tract infections*.  
   epidemiology of, 472-475
- Pneumonitis, drug-induced, 739-741  
   interstitial, lymphocytic, in Sjögren's syndrome, 712  
   lupus, acute, treatment of, 685
- Polyangiitis overlap syndrome, 668
- Polychondritis, relapsing, 710-711
- Polycythemia, pulmonary involvement in, 735-736
- Polymyositis/dermatomyositis, pulmonary involvement in, 706-708
- Postcardiac injury syndrome, clinical manifestations and treatment of, 573-574
- Posture, during testing, in predictions of normal values for PFTs, 138
- Potassium channels, in alveolar macrophages, 31-32  
   in endothelial cells, 33  
   in tracheal epithelial cells, 29-30  
   in type II alveolar epithelial cells, 30-31
- Predicted normal values, in pulmonary function testing, 135-143  
   accuracy of, factors affecting, 136-139  
   future considerations, 141-142  
   importance of, 135-136  
   lower limits of normal in, 140-141  
   recommendations for testing, 141  
   selection of subjects for reference, 139-140  
   in trained athletes, singers, and wind instrument players, 139
- Prednisone, for Wegener's granulomatosis, 667
- Pregnancy, changes during, effect on DLCO, 192
- Prisons, tuberculosis in, 402-404
- Probes, in diagnosis of tuberculosis, 318-319
- Procainamide, as cause of lupuslike syndrome, 694-695  
   as cause of lupus syndrome, 578-579
- Prostate carcinoma, metastasis to lung, 767
- Pulmonary artery ligation, effect on pulmonary metabolic function, 5-6
- Pulmonary disease, applications of molecular biology to, 119-125  
   role of PAF in, 115
- Pulmonary edema, neurogenic, and respiratory function, 525-527
- Pulmonary emboli, septic, causes of, 579
- Pulmonary embolism, clinical presentation, evaluation and treatment, 728-730
- Pulmonary fibrosis, interstitial, in rheumatoid arthritis, 698-700
- Pulmonary function, abnormalities in, congenital heart disease and, 570-571
- Pulmonary function laboratory, 129-134  
   infection control and safety in, 130-132  
   instrumentation in, 132  
   personnel in, 129-130  
   quality control in, 132-133
- Pulmonary function testing, abnormalities in, with chronic congestive heart failure, 567-570  
   applications of, 135  
   in assessment of respiratory muscle function, 204-205  
   infection control and safety in, 130-132  
   interpretation of, effect of chronic liver diseases on, 605-607

- Pulmonary function testing (*Continued*)  
 issue on, 129-291  
 prediction of normal values in, 135-143  
 in scleroderma, 703-705
- Pulmonary function tests, types of, 145-146
- Pulmonary hemorrhage, 724-728  
 clinical presentation of, 724-725  
 diagnostic evaluation of, 727  
 differential diagnosis of, 725-727  
 treatment of, 727-728
- Pulmonary hypertension, in chronic liver disorders, 600-601
- Pulmonary infection, mycobacterial, 419-429  
 in systemic lupus erythematosus, 692-693
- Pulmonary metabolic functions, clinical observations of, 9  
 effect of acute lung injury on, 7-9  
 effect of alveolar and blood gas tensions and pH on, 6  
 effect of emphysema on, 5-6  
 effect of left atrial hypertension on, 5  
 effect of lung inflation on, 5-6  
 effect of microembolism on, 5-6  
 effect of postnatal development of pulmonary microcirculation on, 6-7  
 effect of pulmonary artery ligation on, 5-6  
 factors affecting, 3-4  
 influence of surface area on, 4-7  
 in the intact organ, measurement of, 2-3  
 interpretation of, 1-12  
 issue on, 1-125
- Pulmonary microcirculation, postnatal development of, effect on pulmonary metabolic function, 6-7
- Pulmonary oxygen toxicity, therapy for patients exposed to, 44-45
- Pulmonary-renal syndromes, 655-675  
 classification of, 656  
 general approach to, 671
- Pulmonary surfactant metabolism, 83-93
- Pulmonary symptoms, evaluation of, bronchoprovocation testing in, 173
- Pulmonary vascular damage, causes of, 559-560
- Pulmonary vascular disease, in atrial septal defects, 557  
 congenital disease and, 550-560  
 in Eisenmenger's syndrome, 557-558  
 in patent ductus arteriosus, 557  
 in pulmonary vascular resistance, 558-559  
 pulmonary venous hypertension and, 560-567  
 in tetralogy of Fallot, 560  
 in ventricular septal defects, 556-557
- Pulmonary vascular endothelium, role in 5-HT uptake, 62-63
- Pulmonary vascular resistance, pulmonary vascular disease in, 558-559
- Pulmonary vasculature, alterations in, cardiac disease and, 545-550  
 normal, anatomy of, 546  
 function of, 546-550
- Pulmonary vasculitis, in rheumatoid arthritis, 702
- Pyrazinamide, in treatment of tuberculosis, 326
- 4-Quinolones, in treatment of tuberculosis, 356-357
- Race, in predictions of normal values for PFTs, 137-138
- Radiography, for measurement of lung volumes, 180
- Reactive airways dysfunction syndrome, diagnosis of, bronchoprovocation testing in, 173-178
- Reactive oxygen metabolites, metabolic success of, during oxidant stress and ischemia with perfusion, 71-81
- Rectum, carcinoma of, metastasis to lung, 768-769
- Renal cell carcinoma, metastasis to lung, 767-768
- Renal disease, pulmonary manifestations of, 671
- Renal failure, respiratory infection in, 480-482
- Renal transplantation, respiratory infection in, 484-485
- Reproductive systemic disorders, pulmonary manifestations of, 650
- Respiration, CNS function in, 521-531  
 neural control of, 521-522  
 neurologic disorders and, 521-543  
 peripheral nervous system in, 531-536
- Respiratory cells, metabolic regulation of, ion channels in, 25-36
- Respiratory disease, manifestations of, caused by systemic lupus erythematosus, 677-697. *See also Systemic lupus erythematosus.*
- Respiratory disorders, during sleep, evaluation of, 265-276. *See also Sleep, respiratory disorders during, evaluation of.*
- Respiratory function, effect of endocrine and metabolic disorders on, 645-653  
 neuropathologic conditions and, 522-531
- Respiratory illness, gastrointestinal causes of, 617-643
- Respiratory muscle control, 531-533
- Respiratory muscle function, clinical and physiologic evaluation of, 199-214  
 anatomical considerations, 199  
 for determining endurance, 207-208  
 for determining strength, 205-207  
 history and physical examination in, 204  
 diaphragmatic contribution to, evaluation of, 208-211  
 role of abdominal muscles in, 201  
 role of diaphragm in, 199-200  
 role of intercostal muscles in, 200  
 role of scalene muscles in, 200-201  
 role of sternocleidomastoid muscles in, 201
- Respiratory muscles, coordination of, 202-203  
 evaluation of, history and physical examination in, 204  
 physiology and metabolism of, 201-202  
 in systemic lupus erythematosus, 689-691
- Respiratory tract, defense mechanism of, normal, 469-470
- Respiratory tract infections, and acute lung injury, in systemic illness, 469-502  
 in alcoholism, 478-479  
 in cancer, 482  
 in chronic liver disease, 478-479  
 in collagen vascular diseases, 479-480  
 in diabetes mellitus, 477-478  
 in Felty's syndrome, 480  
 in heart disease, 482  
 in malnutrition, 486-487  
 in renal failure, 480-482  
 in rheumatoid arthritis, 480  
 in Sjögren's syndrome, 480  
 in systemic illness, advanced age and, 475-477  
 treatment of, 487-488  
 in systemic lupus erythematosus, 479-480  
 in transplantation, 483-486
- Restrictive lung diseases, lung volume measurements in, 183-184
- Rifabutin, in treatment of tuberculosis, 357  
 drug-resistant, 350-351
- Rifampin, in treatment of tuberculosis, 325-326, 357
- Rifamycins, in treatment of tuberculosis, 357-358
- Rifapentine, in treatment of tuberculosis, 357
- RNA probes, role in diagnosis and treatment of pulmonary disease, 121
- Roxithromycin (RU-28965), in treatment of tuberculosis, 358-359

- Scalene muscles, role in respiratory muscle function, 200-201
- Scleroderma, 703-706  
 evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714  
 lung cancer and, 705  
 lymphocytic interstitial pneumonitis in, in Sjögren's syndrome, 712  
 pulmonary complications of, 705  
 pulmonary function testing in, 703-705  
 respiratory disease in, treatment of, 705-706
- Sclerosis, systemic, progressive. *See Scleroderma.*
- Seizures, pulmonary complications of, 527-528
- Sepsis, definition of, 489  
 effects on acute lung injury, 493  
 as a risk factor for ARDS, 490-491  
 systemic, and acute lung injury, 488-493  
   clinical syndrome of, 492-493  
   pathology of, 491-492  
   and indirect lung injury, mechanisms of, 491  
   respiratory effects of, 489-490
- Serotonin (5-HT), lung metabolism of, 59-70  
 role in pathophysiology of lung disease, 65-67  
 synthesis, distribution, and physiology of, 59-61
- Serotonin (5-HT) uptake, effects of lung injury on, 63-65  
 in lung disease, applications and limitations of measuring, 67-68  
 and metabolism in normal lung, 61-62  
 role of pulmonary vascular endothelium in, 62-63
- Sex, in predictions of normal values for PFTs, 137  
 and tuberculosis, 304
- Short-term maximal power output, cardiopulmonary, 280
- Shy-Drager syndrome, and respiratory function, 536-537
- Sickle cell anemia, pulmonary involvement in, 730-733
- Single-breath techniques, for assessing DLCO, 189
- Sjögren's syndrome, 711-712  
 evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714  
 interstitial lung disease in, 712  
 respiratory infection in, 480
- Skin disease, nontuberculous mycobacteria as cause of, 414
- Sleep, respiratory disorders during, evaluation of, 265-276  
 continuous nasal positive airway pressure treatment for, 269  
 interpretation of results, 273-274  
 monitoring techniques for, 266-269  
 multiple sleep latency test for, 266, 269-271  
 routine respiratory sleep study for, 269  
 types of studies, 266
- Smoking, effect on DLCO, 192  
 history of, in predictions of normal values for PFTs, 138  
 and tuberculosis, 309
- Sodium transport, in tracheal epithelial cells, 29
- Soft tissue, sarcomas of, metastasis to lung, 774-775
- Soft-tissue disease, nontuberculous mycobacteria as cause of, 414
- Spastic dysphonia, and respiratory function, 524-525
- Spinal cord injury, cervical, and respiratory function, 530-531
- Spirometers, accuracy of, 149-150  
 ATS recommendations for, 148-149  
 quality control of, 150  
 types of, performance by, 150-151
- Spirometry, and flow-volume curves, 145-154  
 reference values in, selection of, 152-153  
 results of, interpretation of, 153  
 test selection and reporting of results, 151-152
- volume-time versus flow volume, 146
- Spondylitis, ankylosing, pulmonary involvement in, 709-710
- Step tests, for exercise testing, 278-279
- Sternocleidomastoid muscles, role in respiratory muscle function, 201
- Steroids, treatment with, and risk of tuberculosis, 309
- Streptomycin, in treatment of tuberculosis, 327
- Sulfasalazine, for inflammatory bowel disease, pulmonary complications of, 629-630
- Sulfonamides, in treatment of tuberculosis, 359-360
- Surface tension in lung, role of surfactant in, 85
- Surfactant, components of, 83-85  
 endogenous, turnover and metabolism of, 85-89  
 exogenous, acute lung injury with, metabolic considerations in treatment of, 91-92  
   turnover and metabolism of, 89-90  
 phospholipid composition in, 83-84  
 pool sizes of, 89  
 regulation of pool size, 89  
 role in reducing surface tension, 85  
 subfractions of, 84-85  
 turnover times of, 90-91  
 "whole", isolation of, 83
- Surfactant-associated proteins, 84
- Systemic disease, airway colonization and, 470-472  
 effect on clinical presentation of pneumonia, 475  
 pneumonia in, epidemiology of, 472-475. *See also* *Pneumonia, in systemic illness.*  
 pulmonary manifestations of, issue on, 469-518  
 respiratory infection in, clinical conditions causing, 475-488  
 respiratory infections and acute lung injury in, 469-502
- Systemic lupus erythematosus, airway in, 688-689  
 drug-induced, manifestations of respiratory disease caused by, 693-695  
 evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714  
 immunologic subsets in, 696-697  
 lung parenchyma in, 681-687  
 lung vasculature in, 687-688  
 manifestations of respiratory disease caused by, 677-679  
   clinical evaluation of patients with, 695-696  
   indirect, 691-693  
   pleura in, 678-681  
   relation of lung involvement to other organ involvement in, 696-697  
   respiratory infection in, 479-480  
   respiratory muscles in, 688-691
- Tetralogy of Fallot, pulmonary vascular disease in, 560
- Thalassemias, pulmonary involvement in, 733-734
- Thioacetazone, in treatment of tuberculosis, 328-329
- Thoracic disease, noninfectious, in systemic lupus erythematosus, 693
- Thrombocytopenia, pulmonary involvement in, 735
- Thrombosis, clinical presentation, evaluation, and treatment of, 729-730
- Thyroid, carcinoma of, metastasis to lung, 769-770
- Thyroid disorders, pulmonary manifestations of, 645-648
- Tocainide pulmonary toxicity, 577
- Tonometers, in analysis of blood, 235
- Tracheal epithelial cells, role of ion channels in, 26-30
- Transplantation, bone marrow, in hematologic malignancy-associated disorders, pulmonary involvement in, 742  
 respiratory infection in, 483-486
- Treadmill, for exercise testing, 278  
 protocols for, 279
- Trimethoprim, in treatment of tuberculosis, 359-360

- Tuberculosis, abdominal, in children and adolescents, 388
- in AIDS, 447-456
    - clinical features of, 447-448
    - diagnosis of, 448-454
    - epidemiology of, 447
    - preventive therapy for, 455-456
    - treatment of, 455
  - among the elderly, 397-401
    - clinical and radiographic presentations, 398
    - diagnosis of, 398
    - in nursing homes, 399-401
    - treatment of, 398-399
  - asymptomatic primary, in children and adolescents, 384
  - bone and joint, in children and adolescents, 387-388
  - cases and rates of, 301
    - geographic locations, 301-302
  - in children and adolescents, 381-395
    - diagnosis of, 389-390
    - epidemiology of, 381-382
    - management of, 390-394
    - primary infection, clinical picture of, 384-386
    - pathogenesis of, 382-384
  - cloning of nucleic acid in diagnosis and treatment of, 119-121
  - community problems related to, 397-406
  - in correctional institutions (prisons), 402-404
    - clinical and radiographic presentations, 403
    - effect of HIV infection on, 404
    - treatment of, 403-404
  - diagnosis of, role of clinician in, 298
  - role of mycobacteriology laboratory in, 315-322
  - disease sites of, 299
  - drug-resistant, 341-353
    - effects of resistance on therapy outcome, 347-348
    - management of multiply resistant cases, 348-349
    - mechanism of resistance, 343-347
    - surgery for, 351
    - treatment of, chemotherapeutic regimens for, 348-351
      - resistance to, 351-352
  - endobronchial, in children and adolescents, 384-385
  - epidemiology of, and AIDS, 308-309
    - and HIV infection, 308-309
    - in US, 297-313
  - extrapulmonary, treatment of, 334-335
  - extrathoracic, in children and adolescents, 386-389
    - of eye and ear, in children and adolescents, 389
  - genitourinary, in children and adolescents, 388
  - immune cells in, 445-446
  - infectiousness of, 299-301
  - in long-term care and mental hospitals, control of, 401-402
  - meningeal, in children and adolescents, 387
  - miliary, in children and adolescents, 386-387
  - morbidity reporting of, 297-299
  - Mycobacterium* species as cause of, 315-316
  - prevention of, environmental control in, 367-368
    - future of, 373-374
    - physician's role in, 365-374
      - administering preventive therapy, 369-371
      - development of strategies, 365-367
      - identifying candidates for preventive treatment, 371-372
      - limiting further transmission, 367-368
      - managing preventive therapy, 372-373
      - prescribing preventive therapy, 372
      - protecting uninfected persons, 368-369
  - progressive primary pulmonary, in children and adolescents, 385-386
  - risk factors for, 302-309, 367
  - role of HIV infection in, 446-447
  - screening in, 309-311
    - high-risk environments, 310-311
    - high-risk occupations, 310
    - low-income populations, 310
  - in shelters for the homeless, 404
  - in short-term facilities (jails), 404
  - of the skin, in children and adolescents, 388-389
  - treatment of, chemotherapeutic regimens in, 329-332
    - background of, 342-343
    - ensuring adherence to, 333
    - evaluating response to, 333-334
    - monitoring of, 332-333
  - current regimens, 323-339
  - drug delivery systems for, 361-362
  - enhancement of patient compliance, 375-390. See also *Behavior, compliance, in tuberculosis therapy.*
  - first-line drugs in, 324-327
  - new antimycobacterial agents for, 335-364
  - second-line drugs in, 327-328
- Uremia, pulmonary manifestations of, 670
- Vascular diseases, collagen. See *Collagen vascular diseases.*
- DLCO in, 194-195
- Vasculitis, systemic necrotizing, 661
- Vasoconstriction, impaired hypoxic pulmonary, in chronic liver disorders, 599-600
- Ventilation, neurophysiologic aspects of, 215-216
  - and ventilatory pattern, measurements of, 217-218

Ventilation-perfusion mismatch, in chronic liver disorders, 599

Ventilatory control, measurements of, carbon dioxide and hypoxia in, 220-224
  - clinical application of, 224-225

Ventilatory monitoring, in sleep studies, 268-269, 271-273

Ventilatory regulation, measurements of, 215-226

Ventricular septal defects, pulmonary vascular disease in, 556-557

Volume-time curves, definition of, 146

von Willebrand's disease, treatment of, 728

Waldenström's macroglobulinemia, pulmonary involvement in, 741-742

Walking tests, for exercise testing, 279

Wegener's granulomatosis, 661-667
  - antineutrophil cytoplasmic antibodies in, 663-664
  - clinical manifestations of, 661-663
  - pathology and diagnosis of, 664-666
  - radiologic features of, 664
  - therapy and prognosis of, 666-667

Weight, in predictions of normal values for PFTs, 137

Whipple's disease, pulmonary manifestations of, 630

Wiskott-Aldrich syndrome, features of, 512-514

Xanthine oxidase, role in ischemia and reperfusion injury, 75-79

Xenobiotic compounds, lung metabolism of, 49-58

